Portal de Periódicos da CAPES

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort

2012; Elsevier BV; Volume: 119; Issue: 25 Linguagem: Inglês

10.1182/blood-2012-04-422204

1528-0020

Raphaël Itzykson, Sylvain Thépot, Bruno Quesnel, François Dreyfus, Christian Récher, Eric Wattel, Claude Gardin, Lionel Adès, Pierre Fenaux,

Chronic Myeloid Leukemia Treatments

To the editor: We previously reported that peripheral blasts, performance status (PS), red blood cell (RBC) transfusion requirement, and International Prognostic Scoring System (IPSS) cytogenetic risk independently predicted inferior overall survival (OS) in 282 consecutive IPSS high- and